Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

Inclusion Criteria: * Male or female healthy adult subjects willing to sign a patient information and consent form (PICF) and able to undergo protocol related procedures. * Age: 18 to 55 years, inclusive. * Body Mass Index (BMI): 18.5 to 32.0 kg/m2. * No history or evidence of a clinically significant disorder, condition, or disease that, in the opinion of the investigator would pose a risk to subject safety. * Resting supine systolic blood pressure of ≤150 mmHg and diastolic blood pressure of ≤90 mmHg. Other vital signs showing no clinically relevant deviations according to the investigator's judgment. * 12-lead ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the investigator. * Negative urine drug screen and negative alcohol breath test at screening and admission. Exclusion Criteria * Subjects will be excluded from the study if one or more of the following criterion are applicable: * Evidence of clinically relevant pathology * History of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) used in study. * Known history of previous exposure to adalimumab or other anti TNF-alpha molecules. * Subjects with a recent (within 6 months of dosing) infection requiring hospitalisation or intravenous antibiotic use. * Subjects with a recent (within 4 weeks of dosing) infection requiring oral or systemic antibiotics. * Subject with a history of recurrent or chronic infections. * Subject has a positive test for tuberculosis (TB) during screening or a known history of active or latent TB, except documented and complete adequate treatment of TB. * Having received live vaccines during the 4 weeks before screening or have the intention to receive vaccination during the study. * Participation in a drug study within 60 days or 5 half-lives of the previous drug (if known), whichever is longer, prior to drug administration Note: Only the few inclusion/exclusion criteria are mentioned here. Subjects will be screened and randomized as per the full list of inclusion and exclusion criteria in the protocol.